New genetic tests could help kids avoid unnecessary transplants after CAR t
NCT ID NCT05621291
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 38 times
Summary
This pilot study tests whether regular, advanced genetic testing of blood and bone marrow can better monitor children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission from CAR T therapy. The goal is to distinguish who is cured by CAR T alone from who may still need a stem cell transplant. Participants aged 1 to 25 will have frequent blood draws and four bone marrow biopsies over two years to see if these tests can predict relapse earlier than standard methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
NOT_YET_RECRUITINGAtlanta, Georgia, 30329, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's National Medical Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber/Boston Children s Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
-
Seattle Children's, University of Washington
RECRUITINGSeattle, Washington, 98105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Next-generation sequencing (NGS) testing
What this could lead to
If successful, this testing approach could help doctors know which children are cured by CAR T alone and which need a stem cell transplant, reducing unnecessary transplants and their side effects.
What could go wrong
This is a small pilot study (60 participants) testing a monitoring strategy, not a treatment. The tests may not reliably predict relapse, and the approach may not improve outcomes in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.